Diamyd Medical AB

Annual Report 08/09

Diamyd® vaccine approved for studies in children down to 3 years of age in the US

Bulletin from shareholders’ meeting: Diamyd stands stronger than ever

Publication of change in the total number of shares and votes in Diamyd

Diamyd Medical publishes the Annual Report for 2008/2009

Additional Pharma Competence proposed for Diamyd Board of Directors

Diamyd’s European Phase III study fully recruited

Summons to the Annual General Meeting of Diamyd Medical AB

Diamyd Technology Advances with US $ 1.84 Million Grant

Diamyd’s new share issue substantially oversubscribed

Diamyd reports successes in Q4

Fourth Quarter Report, Stockholm, October 23, 2009

Diamyd receives compensation from Apoteket AB

Publication of a prospectus relating to the fully underwritten new rights issue in Diamyd Medical AB

Extra shareholders’ meeting at Diamyd Medical AB approves a new share issue of 220 MSEK

Diamyd close to important milestone

Diamyd makes investment in time-to-market

Diamyd implements fully underwritten rights issue and strengthens negotiation position

4 year follow-up of Diamyd® Phase II study shows clear positive trend

Diamyd to include children and accelerate patient recruitment in US Phase III study with the Diamyd® diabetes vaccine

Important progress for Diamyd Medical during the third quarter

Third quarter report for Diamyd Medical AB (publ), fiscal year 2008/2009

Diamyd Medical has treated half of the patients in European registration study

Diamyd® study published in Europe’s leading scientific diabetes journal

President and CEO Elisabeth Lindner comments on the second quarter

Second quarter report for Diamyd Medical AB (publ), fiscal year 2008/2009

Diamyd´s subscription warrant provides SEK 28 million cash injection

Diamyd discussing potential consolidation of Phase III trials

Diamyd Majority owners exercise 10,000 warrants each

Diamyd Medical licenses novel Pain Product